Talk:Vivek Ramaswamy: Difference between revisions

Content deleted Content added

Inline

Revision as of 07:23, 27 January 2019

	Biography portal This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles
???	This article has not yet received a rating on Wikipedia's content assessment scale.

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

FinalFrontier.003 (talk · contribs) has been paid by Vivek Ramaswamy. Freelancer; disclosed here

Edit requests from COI editor

It is requested that an edit be made to the extended-confirmed-protected article at Vivek Ramaswamy. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any extended confirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{EEp}} template in the response. To request that a page be protected or unprotected, make a protection request.

I'm a declared COI editor starting to work on Vivek Ramaswamy's page. I have not worked on his page prior to this message. I'm hoping to reshape the page and work with editors to remove the tag. I'm requesting one edit at the moment.

Extended content

Axovant Sciences is one of the many subsidiaries that Vivek founded and it does not make sense to give this priority or for it to have its own sentence. Therefore, I'd like to change the following. I've added references for the three subsidiaries that would be new to the page.

Current wording: He is also the founder of Axovant Sciences, a clinical-stage pharmaceutical company focusing on treatments for dementia, and the founder of other subsidiaries including: Altavant[1], Aruvant[2], Axovant, Datavant, Dermavant, Enzyvant, Myovant, Urovant[3], Genevant[4], Immunovant[5], Metavant[6], and Respivant[7].

Requested wording: He is the founder of many subsidiaries including: Axovant Sciences^[1], Altavant[1], Aruvant[2], Axovant, Datavant, Dermavant, Enzyvant, Myovant, Urovant[3], Genevant[4], Immunovant[5], Metavant[6], and Respivant,[7] Sinovant^[2], and Alyvant^[3].

References

^ Grover, Natalie. "Acadia drug approval could clear way for Axovant dementia therapy". Reuters. Retrieved 27 January 2019.
^ Keown, Alex. "Roivant Launches New China-Based Startup Sinovant Sciences". BioSpace. Retrieved 27 January 2019.
^ Grover, Natalie. "Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another 'Vant'". Endpoints News. Retrieved 27 January 2019.

Thank you for your help, FinalFrontier.003 (talk) 07:23, 27 January 2019 (UTC)[reply]

[Reuters_Axovant-1] Grover, Natalie. "Acadia drug approval could clear way for Axovant dementia therapy". Reuters. Retrieved 27 January 2019.

[BioSpace_Sinovant-2] Keown, Alex. "Roivant Launches New China-Based Startup Sinovant Sciences". BioSpace. Retrieved 27 January 2019.

[Endpoints_News_Alyvant-3] Grover, Natalie. "Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another 'Vant'". Endpoints News. Retrieved 27 January 2019.

[1]

[2]

[3]

@@ Line 2: / Line 2: @@
 {{Connected contributor (paid)
 | User1  =FinalFrontier.003  | U1-employer  = Vivek Ramaswamy     | U1-client  =  | U1-EH  =  | U1-banned  =     | U1-otherlinks  = Freelancer; disclosed [https://en.wikipedia.org/w/index.php?title=User%3AFinalFrontier.003&type=revision&diff=868618238&oldid=866595107 here]}}
+== Edit requests from COI editor ==
+{{request edit}}
+I'm a declared COI editor starting to work on Vivek Ramaswamy's page. I have not worked on his page prior to this message. I'm hoping to reshape the page and work with editors to remove the tag. I'm requesting one edit at the moment.
+{{collapsed top}}
+Axovant Sciences is one of the many subsidiaries that Vivek founded and it does not make sense to give this priority or for it to have its own sentence. Therefore, I'd like to change the following. I've added references for the three subsidiaries that would be new to the page.
+Current wording: He is also the founder of Axovant Sciences, a clinical-stage pharmaceutical company focusing on treatments for dementia, and the founder of other subsidiaries including: Altavant[1], Aruvant[2], Axovant, Datavant, Dermavant, Enzyvant, Myovant, Urovant[3], Genevant[4], Immunovant[5], Metavant[6], and Respivant[7].
+Requested wording: He is the founder of many subsidiaries including: Axovant Sciences<ref name="Reuters Axovant">{{cite web |last1=Grover |first1=Natalie |title=Acadia drug approval could clear way for Axovant dementia therapy |url=https://www.reuters.com/article/us-axovant-sciences-dementia-idUSKCN0XP2IL |publisher=Reuters |accessdate=27 January 2019}}</ref>, Altavant[1], Aruvant[2], Axovant, Datavant, Dermavant, Enzyvant, Myovant, Urovant[3], Genevant[4], Immunovant[5], Metavant[6], and Respivant,[7] Sinovant<ref name="BioSpace Sinovant">{{cite web |last1=Keown |first1=Alex |title=Roivant Launches New China-Based Startup Sinovant Sciences |url=https://www.biospace.com/article/roivant-launches-new-china-based-startup-sinovant-sciences/ |publisher=BioSpace |accessdate=27 January 2019}}</ref>, and Alyvant<ref name="Endpoints News Alyvant">{{cite web |last1=Grover |first1=Natalie |title=Positive ocular implant data bring Allergan one step closer to NDA; Vivek Ramaswamy spawns another ‘Vant’ |url=https://endpts.com/protocols-positive-ocular-implant-data-brings-allergan-one-step-closer-to-nda-vivek-ramaswamy-spawns-another-vant/ |publisher=Endpoints News |accessdate=27 January 2019}}</ref>.
+{{reftalk}}
+{{cob}}
+Thank you for your help, [[User:FinalFrontier.003|FinalFrontier.003]] ([[User talk:FinalFrontier.003|talk]]) 07:23, 27 January 2019 (UTC)